AOD 9604 vs semaglutide leaves a few fair questions.
Here are the distinctions we'd want clear without keeping six browser tabs open.
An honest gap can stay a gap.
Which has human weight-loss evidence?
Semaglutide does. AOD-9604's human obesity trial didn't establish significant weight loss beyond placebo, the comparison treatment without the active ingredient. We don't put those records on equal footing just because both compounds appear in peptide searches.
A trial comparing semaglutide with tirzepatide gives one direct example of semaglutide's human results. Both groups lost weight on average. Participants had obesity without type 2 diabetes; Lilly funded the study, and everyone knew which treatment they received.
The trial didn't include AOD-9604. It can't supply a direct difference between AOD-9604 and semaglutide. Our comparison page explains what we can still learn from their different records.
Does tolerating AOD-9604 mean it works?
Those are separate questions. The human report describes a tolerability experience resembling placebo. That doesn't undo the failed weight-loss result. Earlier mouse experiments don't establish a treatment benefit for people either.
What about CJC-1295 or ipamorelin?
The sources here don't contain a controlled human comparison that ranks either against AOD-9604 for weight loss. We can't turn the missing comparison into a personal combination plan.
Is tesamorelin another weight-loss choice?
The approval for EGRIFTA WR (tesamorelin) covers reducing extra abdominal fat in adults affected by HIV-associated lipodystrophy. That condition shifts where body fat sits. Its label excludes weight-loss management.
A separate small trial in adults with HIV measured visceral and liver fat. Visceral fat sits around the organs. Fatty liver isn't an approved use, and that study doesn't establish general weight-loss benefit.
Our tesamorelin page explains the distinction and the monitoring cautions.
Can a clinician say no?
Yes. Your medical history, the goal and a medicine's warnings all matter. A published result doesn't establish that you qualify.
For example, the tirzepatide label rules out use with certain thyroid-cancer histories. A clinician's refusal can be a useful answer, even when you arrived with a clear preference.
And what does approval cover?
An approval covers the named product for specified purposes. Compounded medicines are not FDA-approved.
The reading list lets you follow these distinctions back to the sources. Personal symptoms and treatment decisions need a clinical conversation.
A useful next question is what the evidence leaves unanswered for your goal. You can bring that uncertainty to a clinician without arriving with a favourite compound already chosen.